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Abstract
Background: Nephrotic syndrome is a disorder characterized by proteinuria, hypoalbuminemia and dyslipidemia.
Low-dose alternate-day steroid regimen is the standard of care. In case of relapse or significant adverse events,
steroid-sparing agents may be used. This analysis was aimed at assessing the efficacy and safety of rituximab for the
treatment of children with nephrotic syndrome.
Results: Four studies were included in the final meta-analysis. The end-point of our analysis was the percentage of
patients in remission at 6 months. Pooled data from the four studies favours the use of rituximab (RR 5.25, 95 % CI:
3.05–9.06; p < 0.0001). As regards the safety data, rituximab has a limited number of adverse effects, the most
common of which occur during the infusions.
Conclusions: In Italy, the off-label use of drugs is regulated by Law 648/96. In our opinion, there are three scientific
requirements to merit a conditional national reimbursement for rituximab in nephrotic syndrome: 1. favourable
clinical efficacy and safety data; 2. no available alternatives; 3. outcome data collecting by AIFA through prescribers.
In conclusion, our results report a significant incremental benefit of adding rituximab to corticosteroid and/or
calcineurin inhibitors for the treatment of nephrotic syndrome.
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Background
Nephrotic syndrome (NS) is a disorder characterized by
heavy proteinuria, hypoalbuminemia (serum albumin
<2.5 g/dl), often associated with dyslipidemia and hyperco-
agulability (Ravani et al. 2015). The most recent update of
the NS clinical guidelines suggests a low-dose alternate-
day steroid regimen as first-line treatment for the manage-
ment of children who develop frequently-relapsing (FRNS)
or steroid-dependent nephrotic syndrome (SDNS) [1].
However, when there is a failure to maintain remission
or significant adverse events occur with corticosteroid
therapy, clinicians have the option of using a number of
steroid-sparing agents such as cyclophosphamide and
calcineurin inhibitors (CIs, e.g., cyclosporin, tacrolimus,
mycophenolate mofetil) or levamisole. Some of these
immunosuppressant agents may cause serious adverse
events such as nephrotoxicity, hyperglycemia, headaches
and dyslipidemia [2]. Therefore, new drugs are needed
to address this problem. Several reports and guidelines
have proposed rituximab as a novel agent for the treat-
ment of children with FRNS/SDNS [1–4].
During an evaluation of the off-label prescription of
drugs in our hospital, we encountered many prescriptions
for rituximab for the treatment of children with NS.
Thus, the aim of this analysis was to assess the efficacy
and safety data of the use of rituximab for the treatment
of children with FRNS/SDNS, in whom the corticosteroid
therapy is not sufficient to manage the disease, and to
provide these quantitative results as meta-analytical data.
Efficacy and safety data
We performed a literature search in PubMed on 13
January, 2016, using the following search terms: neph-
rotic syndrome AND rituximab; limits, clinical trials.
The search identified 21 articles. After screening the
titles and the abstracts, 3 studies underwent full-text
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screening [5–7]. Any randomised controlled trial ad-
dressing effectiveness and/or safety of rituximab for
children with complicated FRNS/SDNS is considered
eligible to be included. The inclusion criteria were the
following: a) children with complicated FRNS/SDNS;
b) rituximab as intervention therapy; c) corticosteroid
therapy and/or CIs as control therapy; d) complete
remission rate as end-point. A fourth study (Ahn et al.
2013 [8]) was extrapolated from the references of the
paper by Iijima et al. 2014. Thus, 4 studies were in-
cluded in the final analysis (Table 1). The intervention
group comprised patients treated with rituximab plus
prednisone and/or CIs, while the control group contained
patients on prednisone and/or CIs. The end-point of our
meta-analysis was the percentage of patients in remission
at 6 months. The data of other end-points (e.g., relapse-
free survival rate for efficacy and adverse events for safety)
were reported as qualitative results. Our meta-analysis
was performed using the RevMan software (version 5.2,
the Nordic Cochrane Centre, Copenhagen, Denmark).
Figure 1 shows the results of the meta-analysis. Pooled
data from the four studies favours the use of rituximab
Table 1 Basic characteristics of included studies. The intervention group comprised patients treated with rituximab plus prednisone
and/or CIs, while the control group contained patients on prednisone and/or CIs. The end-point of our meta-analysis was the



















6.9/6.9 19/11 All patients were maintained in remission
with high prednisone doses (>0.7 mg/kg
per day)
Treatment group
- RTX (one infusion of 375 mg/m2)
- prednisone was tapered off by 0.3 mg/kg
per week if proteinuria was <1 g/d.
Control group





RTX (27) Corticosteroid +
CIs therapy (27)
10.2/11.3 43/11 Treatment group




- prednisone was tapered off by 0.3 mg/kg
per week if proteinuria was <1 g/d.
Control group
- prednisone and CIs (tapered off by 0.3 mg/kg







11.5/13.6 34/14 Treatment group
- RTX an intravenous dose of 375 mg/m2
(maximum





- prednisolone (60 mg/m2 orally three times
a day (maximum of 80 mg per day) for





RTX (35) Corticosteroid +
CIs therapy (18)
13/NA NA/NA Treatment group
- single dose of intravenous RTX (375 mg/m2)
Control group
- corticosteroid therapy
FRNS or SDNS were defined complicated as follows: a) children when aged 2 years or older, who had ≥4 relapses in a 12-month period or steroid dependence at
any point in the 2 years before relapse at screening, after completion of immunosuppressive drug treatment (e.g., ciclosporin, cyclophosphamide, mizoribine, or
mycophenolate mofetil); or b) children when aged 2 years or older, who had ≥4 relapses in a 12-month period or steroid dependence diagnosed at any point in
the 2 years before relapse at screening, during immunosuppressive drug treatment (e.g., ciclosporin, cyclophosphamide, mizoribine, or mycophenolate mofetil); or
c) patients with a history of SRNS and diagnosed with FRNS or SDNS when aged 2 years or older, who had ≥4 relapses in a 12-month period or steroid
dependence at any point in the 2 years before relapse at screening, during or after the completion of immunosuppressive drug treatment (e.g., ciclosporin
or a combination of ciclosporin and methylprednisolone)
Abbreviations: CIs calcineurin inhibitor, RTX rituximab, NA not available
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as regards patients in remission at 6 months (RR 5.25,
95 % CI: 3.05–9.06; p < 0.0001). At 12 months, these
results were also confirmed in two of the four above
mentioned RCTs [5, 6]. The study by Iijima et al. 2014
reported that a median relapse-free survival rate
favoured rituximab vs. control therapy (HR 0.27, 95 %
CI: 0.14–0.53; p < 0.0001). The same results were re-
ported by Ravani et al. 2014 (HR 0.39, 95 % CI: 0.22–
0.67; p = 0.03). In the study by Ahn et al. 2014, these
data were not available.
As regards the safety data, rituximab has a limited
number of adverse effects, the most common of which
occur during the infusions [5, 6]. In the study by Iijima
et al. 2014, most adverse events for rituximab were mild,
and no patient died during the trial. Although more pa-
tients in the rituximab group had serious adverse events
compared to controls, the difference was not significant
(p = 0.36). The most common grade 3–4 adverse events
in the rituximab group were hypoproteinemia, lympho-
cytopenia and neutropenia.
Both studies by Ravani et al. report similar safety data,
the most common adverse events being bronchospasm,
hypotension (at the second rituximab infusion), skin
rash, acute arthritis at the hip joint after 2 and 6 days
from the infusion (resolution was rapidly and completely
achieved within 24 to 48 h with non-steroidal anti-
inflammatory medications). In the study by Ahn et al.
2014, 24 of the 54 treated patients (44 %) experienced
mild and transient infusion reactions, however, no ser-
ious side effects were observed.
Discussion
In Italy, the off-label use of drugs is currently regulated
by Law 648/96. According to this regulation, medicines
can be used off-label at NHS expense, once the Italian
Medicine Agency (Agenzia Italiana del Farmaco, AIFA
[9]) has authorised their inclusion on a specific list. The
inclusion on this list requires the coexistence of three el-
ements: favourable clinical efficacy and safety data; no or
scant alternatives for treating the disease; outcome data
collection by AIFA through prescribers. In our opinion,
all the above mentioned requirements are met to merit a
conditional national reimbursement for rituximab in NS
through the law 648/96. However, the third requirement
(e.g., collection of outcome data) should be made
more stringent by AIFA and, in this case, it would
allow for a pharmaco-epidemiological description of
the treatments performed nationwide, compared to
the current situation in which each individual hospital
manages and analyses its own small pool of patients.
The cost of one infusion of rituximab (375 mg/m2) is
1,943 euros/patient (this cost does not take into ac-
count any eventual nationally-negotiated procure-
ment discount).
A new humanized anti-CD20 antibody - ofatumu-
mab - has been developed and is currently being
tested in two clinical trials: 1. Ofatumumab vs rituximab
for children with SDNS (trial identifier NCT02394106
[10]); 2. ofatumumab vs placebo for children with FRNS
(Basu 2014; Bonanni et al. 2015; trial identifier
NCT02394119 [11–13]). The results are expected in
the coming years; therefore, to date, rituximab is the
best available alternative therapy to corticosteroids
and/or CIs. The cost for one infusion of ofatumumab
(1500 mg/m2) is 6,268 euros/patient (this cost does
not take into account any eventual nationally-negotiated
procurement discount).
The important aspects related to the price and the
costs of these two monoclonal antibodies need to be
taken into consideration. On one hand, rituximab is a
well-known monoclonal antibody that became off-patent
in Europe in November 2013 [14], although it is not yet
marketed as such; on the other hand, ofatumumab is a
new monoclonal antibody with a hypothetical future
conditional approval for the treatment of children with
NS, which costs more and, up to now, has less evidence
supporting its use than rituximab does. In other words,
to date, the reimbursement of rituximab under Law 648/
96 might represent a cost-saving opportunity for the
NHS to provide a treatment option for children with
complicated FRNS/SDNS, in spite of the limited
favourable supporting evidence available, at a lower
price than ofatumumab, in case both drugs are in-
cluded on the 648/96 list.
Fig. 1 Forest plot showing a meta-analysis for rituximab treatment group versus control treatment group on complete remission rate at 6 months
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Conclusion
The results of our updated meta-analysis report a sig-
nificant incremental benefit of adding rituximab to
corticosteroids and/or CIs when treating children with
complicated FRNS/SDNS.
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